India at 75: Changes in nation's pharmaceutical industry since it gained independence
India now has a global reputation for producing high-quality, low-cost generic drugs. According to reports, India’s pharmaceutical industry is expected to be worth US$42 billion in 2021.
Glenmark, Sun Pharma, and Dr Reddy's all recall products in United States
Leading generic drugmakers Glenmark, Sun Pharma, Dr Reddy’s Laboratories, and Jubilant Cadista are recalling a number of products in the United States, the world’s largest market for medicines, due to a variety of issues.
Canakinumab as an adjuvant therapy in lung cancer did not perform as anticipated in a phase III study: Novartis
Novartis announced on Monday that the Phase III CANOPY-A study, which compared canakinumab (ACZ885) to placebo, did not meet its primary endpoint of disease-free survival (DFS).
Sun Pharma receives CDSCO approval to study Elagolix 150 mg for endometriosis
Denying the request to conduct a Phase III study of Elagolix 200mg Tablets with test arm 2, the Central Drug Standard Control Organization’s Subject Expert Committee has recommended that Sun Pharma conduct a Phase III clinical trial of Elagolix 150 mg tablets.
The resurgence of domestic pharmaceutical market boosts confidence
NSE Pharma Index has recovered nearly 9% from its June lows. Although on a high base, the pharmaceutical market has shown signs of recovery since June after a tepid April and May, even though some of the gains can be attributed to improving equity sentiment.
Pharma division of Piramal Enterprises' receives NCLT approval for demerger
NCLT approved the demerger of Piramal Enterprises’ pharma business, with the parent company now keeping the financial services business. This paves the way for the establishment of two distinct listed entities, Piramal Enterprises and Piramal Pharma.
Industry requests an exemption from trade margin rationalization for non-scheduled drugs priced below Rs. 100 from NPPA
The pharmaceutical industry has petitioned the
National Pharmaceutical Pricing Authority (NPPA)
to exempt non-scheduled formulations priced
below Rs. 100 from trade margin rationalization
(TMR) and to phase it in while protecting the
interests of MSMEs.
